| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05254743) | Loxo Oncology, Inc. | 2022-07-22 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572) | Newave Pharmaceutical Inc | 2022-05-08 |
| A Study to Investigate the Efficacy and Safety of MS-553 in CLL/SLL (NCT05272813) | Shenzhen MingSight Relin Pharmaceuticals Co., Ltd. | 2022-04-28 |
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (NCT05287984) | Institute of Hematology & Blood Diseases Hospital, China | 2022-03-22 |
| PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies (NCT05107856) | Prelude Therapeutics | 2022-03-22 |
| Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (NCT05183854) | University of Utah | 2022-01-31 |
| Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL (NCT05153330) | Biomea Fusion Inc. | 2022-01-24 |
| Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL (NCT05147467) | Ascentage Pharma Group Inc. | 2021-12-28 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| Study on the Diagnosis and Management of CLL in Italy by GIMEMA (NCT04867915) | Gruppo Italiano Malattie EMatologiche dell'Adulto | 2021-10-13 |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (NCT05023980) | Loxo Oncology, Inc. | 2021-09-23 |
| A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (NCT04965493) | Loxo Oncology, Inc. | 2021-09-20 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716) | BeOne Medicines | 2021-09-13 |
| NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers (NCT05020678) | Nkarta, Inc. | 2021-08-20 |
| A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL (NCT04722172) | Memorial Sloan Kettering Cancer Center | 2021-05-21 |
| First in Human Study of NVG-111 in Relapsed/Refractory ROR1+ Malignancies (NCT04763083) | NovalGen Ltd. | 2021-05-14 |
| A Study of FCN-338 in Patients With Chronic CLL/SLL (NCT04682808) | Fochon Pharmaceuticals, Ltd. | 2021-05-13 |
| Safe Accelerated Venetoclax Escalation in CLL (NCT04843904) | Dana-Farber Cancer Institute | 2021-04-14 |
| Immune Response to SARS-CoV-2 (COVID-19) Vaccines in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04852822) | University of Washington | 2021-03-18 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study (NCT04269902) | National Cancer Institute (NCI) | 2021-03-02 |
| Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies (NCT04504708) | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | 2021-02-17 |
| ICP-022 Versus Chlorambucil Combined With Rituximab in the Treatment of Untreated CLL/SLL (NCT04578613) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-01-08 |
| A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (NCT04694560) | Memorial Sloan Kettering Cancer Center | 2020-12-22 |
| Study of LUCAR-20S in Patients With R/R NHL (NCT04176913) | The First Affiliated Hospital with Nanjing Medical University | 2020-12-01 |
| Ibrutinib for the Treatment of Patients With B-Cell Malignancies Who Are Infected With Coronavirus Disease 2019 (COVID-19) (NCT04665115) | Academic and Community Cancer Research United | 2020-11-23 |
| Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL (NCT04560322) | Massachusetts General Hospital | 2020-10-19 |
| Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (NCT03639324) | Virginia Commonwealth University | 2020-10-02 |
| Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers (NCT04553692) | IGM Biosciences, Inc. | 2020-09-23 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762) | C. Babis Andreadis | 2020-09-11 |
| Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia (NCT04505254) | M.D. Anderson Cancer Center | 2020-08-25 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (NCT04542824) | Genmab | 2020-08-20 |
| A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies (NCT04279405) | Shanghai YingLi Pharmaceutical Co. Ltd. | 2020-06-15 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab (NCT04282018) | BeiGene | 2020-04-29 |
| Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL (NCT04030195) | Precision BioSciences, Inc. | 2020-03-24 |
| Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL (NCT04155710) | Iovance Biotherapeutics, Inc. | 2020-02-19 |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT04155840) | University of Washington | 2020-01-31 |
| Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma (NCT03892044) | David Bond, MD | 2019-11-05 |
| Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice (NCT04094051) | The First Affiliated Hospital with Nanjing Medical University | 2019-10-01 |
| Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma (NCT03828448) | TG Therapeutics, Inc. | 2019-07-10 |
| Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL (NCT03960840) | Novartis Pharmaceuticals | 2019-06-26 |
| Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL (NCT03572634) | Sumitomo Pharma America, Inc. | 2019-06-10 |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) (NCT03801525) | TG Therapeutics, Inc. | 2019-05-16 |
| A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas (NCT03893682) | Aptose Biosciences Inc. | 2019-04-30 |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (NCT03740529) | Loxo Oncology, Inc. | 2019-03-15 |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) (NCT03666000) | Imugene Limited | 2019-03-11 |
| Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia (NCT03701282) | National Cancer Institute (NCI) | 2019-02-12 |
| Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia (NCT03737981) | National Cancer Institute (NCI) | 2019-01-31 |
| A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia (NCT03734016) | BeiGene | 2018-11-01 |
| Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT03516617) | Mayo Clinic | 2018-09-10 |
| A Study Of The Selective PKC-β Inhibitor MS- 553 (NCT03492125) | MingSight Pharmaceuticals, Inc | 2018-05-25 |
| TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas (NCT03410901) | Ronald Levy | 2018-04-09 |
| Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders (NCT03314974) | Masonic Cancer Center, University of Minnesota | 2018-03-30 |
| A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL) (NCT04771507) | Jeanette Lundin | 2018-02-23 |
| Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (NCT03370185) | SecuraBio | 2018-02-12 |
| A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies (NCT03088878) | Oncternal Therapeutics, Inc | 2018-01-03 |
| A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (NCT03336333) | BeiGene | 2017-10-31 |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies (NCT03263637) | AstraZeneca | 2017-10-24 |
| 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation (NCT03133221) | University of Maryland, Baltimore | 2017-10-23 |
| Study of CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell (NCT03019055) | Medical College of Wisconsin | 2017-10-16 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma (NCT03096782) | M.D. Anderson Cancer Center | 2017-10-13 |
| A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma (NCT03078855) | Jonathan Friedberg | 2017-09-07 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma (NCT03035331) | Mayo Clinic | 2017-08-15 |
| Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (NCT02952508) | Cellectar Biosciences, Inc. | 2017-07-26 |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) (NCT03162536) | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | 2017-06-26 |
| Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers (NCT03037645) | Sunesis Pharmaceuticals | 2017-04-28 |
| Allo HSCT Using RIC for Hematological Diseases (NCT02661035) | Masonic Cancer Center, University of Minnesota | 2017-03-09 |
| Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies (NCT02991898) | Masonic Cancer Center, University of Minnesota | 2017-02-16 |
| Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome (NCT02846623) | M.D. Anderson Cancer Center | 2017-01-31 |
| Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases (NCT01962636) | Masonic Cancer Center, University of Minnesota | 2016-12-01 |
| Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (NCT02639910) | MorphoSys AG | 2016-11-01 |
| Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL) (NCT02910583) | Pharmacyclics LLC. | 2016-09-28 |
| Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (NCT02877082) | Emory University | 2016-09-01 |
| Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects (NCT02825836) | Telios Pharma, Inc. | 2016-08-26 |
| Venetoclax and Ibrutinib in Treating Patients With Chronic or Small Lymphocytic Leukemia (NCT02756897) | M.D. Anderson Cancer Center | 2016-07-07 |
| A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor (NCT02640833) | AbbVie | 2016-07-01 |
| Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL (NCT02784834) | Michael Choi | 2016-06-01 |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (NCT02793583) | TG Therapeutics, Inc. | 2016-05-25 |
| Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma (NCT02339922) | University of Washington | 2016-05-19 |
| Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia (NCT02629809) | M.D. Anderson Cancer Center | 2016-03-18 |
| Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02518555) | Jennifer Woyach | 2016-01-12 |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies (NCT02529813) | M.D. Anderson Cancer Center | 2015-12-16 |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02623920) | University of Arizona | 2015-12-16 |
| A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL (NCT02514083) | National Heart, Lung, and Blood Institute (NHLBI) | 2015-12-09 |
| Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies (NCT02556931) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2015-12-01 |
| A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA) (NCT02576275) | SecuraBio | 2015-12-01 |
| Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma (NCT02258529) | Gilead Sciences | 2015-09-14 |
| Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL (NCT02337829) | Acerta Pharma BV | 2015-01-12 |
| Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma (NCT02258555) | Gilead Sciences | 2015-01-01 |
| Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL (NCT02296918) | Acerta Pharma BV | 2014-12-22 |
| Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) (NCT02242045) | Gilead Sciences | 2014-10-01 |
| Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) (NCT02208037) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-08-01 |
| A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL (NCT02135133) | Dana-Farber Cancer Institute | 2014-06-01 |
| Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) (NCT02200848) | Georgetown University | 2014-04-01 |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT02048813) | National Cancer Institute (NCI) | 2014-03-10 |
| A Phase II Study of Doxycycline in Relapsed NHL (NCT02086591) | University of Rochester | 2014-03-01 |
| Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) (NCT02046928) | Ångstrom Pharmaceuticals | 2014-02-01 |
| ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia (NCT02029443) | Acerta Pharma BV | 2014-01-30 |
| T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies (NCT01163201) | Masonic Cancer Center, University of Minnesota | 2014-01-01 |
| A Phase 3 Extension Study of Duvelisib and Ofatumumab in Participants With CLL/SLL Previously Enrolled in Study IPI-145-07 (NCT02049515) | SecuraBio | 2013-12-01 |